Bio-Rad Laboratories (BIO-B) EBT Margin (2009 - 2026)

Bio-Rad Laboratories (BIO-B) has 18 years of EBT Margin data on file, last reported at 116.5% in Q1 2026.

• EBT Margin for Q1 2026 came in at 116.5%, down 13075.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 8.58% (up 11681.0% YoY), and the FY2025 annual result was 38.54%, up 12981.0% from the prior year.
• EBT Margin slipped to 116.5% in Q1 2026 per BIO-B's latest filing, from 134.05% in the prior quarter.
• Over five years, EBT Margin peaked at 149.45% in Q4 2022 and troughed at 623.91% in Q1 2022.
• A 5-year average of 66.76% and a median of 12.53% in 2023 frame the typical range for EBT Margin.
• The sharpest annual moves came in 2022 and 2023: EBT Margin slumped 80239 bps in 2022, then soared 63644 bps in 2023.
• A 5-year view of EBT Margin shows it stood at 149.45% in 2022, then sank by 58 bps to 62.89% in 2023, then sank by 317 bps to 136.16% in 2024, then jumped by 198 bps to 134.05% in 2025, then plunged by 187 bps to 116.5% in 2026.
• Business Quant data shows BIO-B's EBT Margin at 116.5% in Q1 2026, 134.05% in Q4 2025, and 66.02% in Q3 2025.